Skip to main content
. 2018 Dec 8;16:75–86. doi: 10.1016/j.jare.2018.11.006

Fig. 2.

Fig. 2

Correlation between the expression of AHR and CYP1B1 and patient clinical and pathological properties. Bars represent the fold change (RQ = 2−ΔΔCt) of mRNA expression non-IBC and IBC patients sub-grouped into different tumour grade (G1, G2, G3). (A) mRNA expression of AHR and CYP1B1 in non-IBC patients show no statistical correlation with tumour grade. (B) mRNA expression of AHR and CYP1B1 significantly correlates with high tumour grade in IBC patients. (C and D) Bars represent mRNA expression of AHR and CYP1B1 in non-IBC and IBC patients sub-grouped with negative and positive lymphovascular invasion (LVI) (C) mRNA expression of AHR and CYP1B1 in non-IBC patients, with no statistical correlation with LVI. (D) mRNA expression of AHR and CYP1B1 significantly correlates with LVI in IBC patients. Data represent mean + SD, *P ≤ 0.05 and **P ≤ 0.001 as determined by one-way ANOVA followed by Tukey’s multiple comparison test. (E and F) Scatter charts showing the positive correlation between the mRNA expression of AHR and CYP1B1 and the number of metastatic lymph nodes in non-IBC and IBC patients, respectively. (G) Representative fields of immunostaining (brown colour) of highly expressed AHR, CYP1B1 and Ki-67 in in paraffin embedded IBC and non-IBC carcinoma tissues. (H and I) Scatter charts showing a strong positive correlation between AHR and CYP1B1 expression and Ki-67 expression in IBC but not non-IBC tissues. Correlation coefficient (r values) were calculated by Pearson’s correlation test.